Company Overview and News
MONTREAL, May 15, 2018 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the “Company” or “Osisko Metals”) (TSX-V:OM) (FRANKFURT:OB51) is pleased to announce assay results from 5 shallow drill holes completed between the L-35 and L-36 deposit areas. Drill hole EM-18-PP-050 intersected 3.84% Zn and 0.92% Pb over 9.25 metres. All reported drill holes intersected near-surface mineralization above 60 metre depths, with multiple mineralized intercepts reported in all holes.
VANCOUVER, B.C., May 14, 2018 (GLOBE NEWSWIRE) -- Strongbow Exploration Inc. (TSX-V:SBW) (“Strongbow” or the “Company”) is pleased to announce its intention to apply for admission of its common shares (the “Common Shares”) to trading on the AIM Market (“AIM”) of the London Stock Exchange (“Admission”). The Company expects that Admission will become effective in June 2018. The Company’s Common Shares will continue to list, in the immediate future, on the TSX-V in Canada.
Good morning, ladies and gentlemen, and welcome to the Osisko Gold Royalties Q1 2018 Results Conference Call. [Operator Instructions]. Please note that this call is being recorded today, May 4, 2018 at 10:00 AM Eastern Time. Today on the call we have Mr. Sean Roosen, Chair of the Board of Directors and Chief Executive Officer of Osisko Gold Royalties; and Mr. Bryan Coates, President of Osisko Gold Royalties.
MONTREAL, May 04, 2018 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (the “Corporation” or “Osisko”) (TSX:OR) (NYSE:OR) announces that, at the annual and special meeting of shareholders held on May 3, 2018, each of the 10 nominees listed in the management information circular filed on March 29, 2018 (the “Circular”) with regulatory authorities were elected as directors of the Corporation.
The following slide deck was published by Osisko Gold Royalties Ltd. in conjunction with their 2018 Q1 earnings call.
* OSISKO GOLD ROYALTIES - IN QUARTER, EARNED 20,036 GOLD EQUIVALENT OUNCES, IN-LINE WITH 2018 ANNUAL GUIDANCE OF 77,500 GEOS TO 82,500 GEOS
MONTREAL, May 03, 2018 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (the “Company” or “Osisko”) (TSX:OR) (NYSE:OR) today announced its consolidated financial results for the first quarter ended March 31, 2018 and an update on matters following quarter-end.
It looks like the precious metals market is preparing for another leg up. If that is the case, silver should perform better than gold.
MONTRÉAL, April 16, 2018 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (TSX:OR) (NYSE:OR) (“Osisko”) is pleased to announce that it has completed the previously announced C$148 million financing transaction (the “Financing”) with Victoria Gold Corp. (TSX-V:VIT) (“Victoria”), pursuant to which Osisko acquired from Victoria a 5% net smelter return (“NSR”) royalty (the “Royalty”) for C$98 million (the “Royalty Purchase”) on the Dublin Gulch property (the “Property”) which hosts the Eagle Gold project located in Yukon, Canada, and purchased from Victoria, on a private placement basis, 100 million common shares of Victoria at a price of C$0.
TORONTO, April 16, 2018 (GLOBE NEWSWIRE) -- Victoria Gold Corp. (TSX:V-VIT) “Victoria” or the “Company” is pleased to announce that it has finalized and executed definitive transaction agreements with Orion Mine Finance (“Orion”), Osisko Gold Royalties Ltd (“Osisko”) and Caterpillar Financial Services Limited (“Cat Financial”) with respect to the previously announced construction financing package totalling approximately C$505 million in aggregate (the “Financing”) that will fully fund the development of the Eagle Gold project through to commercial production.
MONTREAL, April 11, 2018 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the “Company” or “Osisko Metals”) (TSX-V:OM) (FRANKFURT:OB51) is pleased to announce additional results from its drill program on the Gilmour South Project located 40 kilometres southwest of Bathurst, New Brunswick. Drill hole GS-18-19 intersected 13.76% Zn, 3.39% Pb, 0.23% Cu and 50.81g/t Ag over 11.00 metres within the targeted massive sulphide trend that now clearly links previous and historical intercepts not previously interpreted as a continuous zone.
Shares of Pretium Resources have been obliterated over the last few months because of grade reconciliation issues at Brucejack.
MONTRÉAL, QUÉBEC--(Marketwired - April 2, 2018) - Osisko Gold Royalties Ltd (TSX:OR)(NYSE:OR) ("Osisko") announces that it has subscribed for and received from Niobay Metals Inc. (TSX VENTURE:NBY) ("Niobay") 9,000,000 common shares of Niobay at a price of $0.26 per share by way of a private placement of Niobay, for an aggregate subscription price of $2,340,000 (the "Private Placement"').
MONTREAL, QUEBEC--(Marketwired - March 29, 2018) - Osisko Metals Incorporated (the "Company" or "Osisko Metals") (TSX VENTURE:OM)(FRANKFURT:0B5) is pleased to announce that it has signed an option agreement (the "Agreement") with Osisko Mining Inc (TSX:OSK) to earn a 50% interest in the Urban-Barry Base Metals Project (the "Project"), a select package of 151 claims located within Osisko Mining's Urban-Barry claim group.
22h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
22h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET